- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03924219
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
Assessment of CMV-specific T Cell Responses by Flow Cytometry With Intracellular Cytokine Staining to Predict CMV Infection Risk in Pediatric Solid Organ Transplant Recipients
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Daniel Dulek, MD
- Phone Number: 615-322-2250
- Email: daniel.dulek@vumc.org
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University Medical Center/Lucile Packard Children's Hospital Stanford
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Medical Center/Children's Hospital of Atlanta
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University Medical Center/Lurie Children's Hospital of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Children's Mercy Hospital
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
New York
-
New York, New York, United States, 10467
- Albert Einstein College of Medicine/Children's Hospital at Montefiore
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center/Duke Children's Hosptial
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children'S Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15224
- University of Pittsburgh Medical Center/Children's Hospital of Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- < 18 years of age at the time of pre-transplant enrollment
- Potential subject is undergoing evaluation or is currently listed for isolated heart, kidney, or liver transplantation at a participating transplant center OR is anticipated to undergo living-donor kidney or liver transplantation
- Anticipated to receive ≤ 200 days of antiviral chemoprophylaxis
Note: Subjects who are consented, enrolled, and undergo transplantation at <18 years of age will remain in the study and be followed post-transplant according to the study plan after they turn 18 years of age. Subjects will be re-consented to remain in the study at their first study visit after turning 18 years of age.
Exclusion Criteria:
I. Exclusion Criteria pre-transplant
- Prior history of any organ transplant
- Prior history of hematopoietic cell transplant
- Anticipated to receive more than one organ at the time of transplant
- Anticipated to receive > 200 days of CMV antiviral chemoprophylaxis as part of the local transplant center's standard CMV prevention protocol
- History of underlying primary (genetic) T cell immune deficiency
II. Exclusion Criteria post-enrollment A) Removal from study due to minimal risk for CMV infection
- CMV seronegative children >= 12 months of age will be enrolled pre-transplant but will subsequently be excluded from the study IF they receive an organ from a CMV seronegative donor (CMV D-/R-).
- Infants <12 months will be considered seronegative regardless of their CMV IgG status (whether or not this testing was obtained by the local transplant center) UNLESS the infant has a positive pre-transplant CMV culture (from urine) or a positive pre-transplant CMV PCR (from urine, saliva, or blood). Infants <12 months of age without evidence of prior CMV infection (as defined by these preceding criteria) will be excluded from post-transplant follow up IF they receive an organ from a CMV seronegative donor due to low risk for post-transplant CMV infection. Infants <12 months of age with evidence of prior CMV infection (as defined above) will remain in the study following transplantation.
B) Removal from study due to age
a. Subjects who are enrolled at <18 years of age but are not transplanted prior to their 18th birthday will be removed from the study and will not have further pre- or post-transplant follow up.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Pediatric Solid Organ Transplant (SOT) Recipients
Pediatric patients (<18 years of age) undergoing or anticipated to undergo solid organ transplantation (heart, kidney, or liver) will be prospectively enrolled with serial blood collection for CMV T cell Immunity Assay performance.
|
Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CMV Infection Incidence
Time Frame: 12 months post-transplantation
|
CMV Infection as measured by CMV DNAemia or CMV disease
|
12 months post-transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of detectable CMV T cell Immunity
Time Frame: 12 months post-transplantation
|
Viracor T cell Immunity Assay
|
12 months post-transplantation
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Daniel Dulek, MD, Vanderbilt University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 180947
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplant Infection
-
Zhejiang UniversityBeijing YouAn Hospital; Beijing Ditan Hospital; Huashan Hospital; Qilu Hospital...Not yet recruitingLiver Transplantation | Transplant Recipients
-
National Hepatology & Tropical Medicine Research...CompletedLiver Transplant InfectionEgypt
-
Minsk Scientific-Practical Center for Surgery,...Enrolling by invitationMicrobial Colonization | Transplantation Infection | Liver Transplant; Complications | Kidney Transplant; Complications | Stem Cell Transplant ComplicationsBelarus
-
Oslo University HospitalSouth-Eastern Norway Regional Health AuthorityNot yet recruitingLiver Metastases | Liver Transplant; Complications | Liver Cancer | Transplant | Transplant; Failure, Liver | Transplant; Complication, Rejection | Transplant Dysfunction
-
Jordan FeldUniversity Health Network, TorontoRecruitingHepatitis C | Kidney Transplant Infection | Heart Transplant Infection | Lung Transplant Infection | Kidney Pancreas InfectionCanada
-
Hospital Vall d'HebronCompletedInfection | Intestinal Microbiota | Complication of Transplanted Liver | Acute Rejection of Liver TransplantSpain
-
Methodist Health SystemEnrolling by invitationLiver Transplant Infection | Kidney Transplant Infection | Polyomavirus Infections | BK ViremiaUnited States
-
University Health Network, TorontoNot yet recruitingSolid Organ Transplant | Liver Transplant | Kidney Transplant | Heart Transplant
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)TerminatedLiver Transplant | Kidney TransplantUnited States
-
Astellas Pharma Europe Ltd.CompletedLiver Transplant | Kidney TransplantItaly, Spain, Belgium, Germany, Latvia, Canada, Korea, Republic of, Czechia, Austria, Finland, Belarus, Estonia, France, Hungary, Ireland, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Sweden, Switzerland, United...
Clinical Trials on CMV T cell Immunity Assay
-
NYU Langone HealthViracor EurofinsNot yet recruiting
-
University of Erlangen-Nürnberg Medical SchoolGerman Research Foundation; Charite University, Berlin, Germany; Ludwig-Maximilians... and other collaboratorsCompletedPatients Undergoing Allogeneic Stem Cell TransplantationGermany
-
Beckman Coulter, Inc.Terminated
-
University Health Network, TorontoCanadian National Transplant Research ProgramCompletedCytomegalovirus ViraemiaSpain, Canada
-
University of Lausanne HospitalsCompleted
-
Nelson ChaoTerminatedCytomegalovirus InfectionsUnited States
-
Meridian Bioscience, Inc.Completed
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingDiffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin LymphomaUnited States
-
University Hospital, GrenobleNot yet recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Cytomegalovirus Infections | Lung TransplantationFrance
-
Chinese PLA General HospitalRecruiting